Published in Hepatology on July 01, 2002
Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut (2005) 5.39
Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci (2010) 3.72
Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol (2006) 3.46
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia (2009) 2.03
Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol (2007) 1.61
The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol (2005) 1.49
Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology (2009) 1.48
Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. Dig Dis Sci (2009) 1.43
Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut (2004) 1.42
Liver diseases and metabolic syndrome. J Gastroenterol (2008) 1.33
Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J Biol Chem (2010) 1.33
Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut (2005) 1.30
Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair (2013) 1.27
Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells. J Cell Biochem (2003) 1.19
Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. Am J Pathol (2008) 1.11
Leptin increases tissue inhibitor of metalloproteinase I (TIMP-1) gene expression by a specificity protein 1/signal transducer and activator of transcription 3 mechanism. Mol Endocrinol (2006) 1.09
Oxidative and nitrosative stress and fibrogenic response. Clin Liver Dis (2008) 1.09
Animal models for the study of liver fibrosis: new insights from knockout mouse models. Am J Physiol Gastrointest Liver Physiol (2011) 1.08
Adiponectin activation of AMPK disrupts leptin-mediated hepatic fibrosis via suppressors of cytokine signaling (SOCS-3). J Cell Biochem (2010) 1.07
Cytokines and STATs in Liver Fibrosis. Front Physiol (2012) 1.02
Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice. Br J Pharmacol (2011) 0.96
In vitro and in vivo protection of stellate cells from apoptosis by leptin. Dig Dis Sci (2006) 0.94
Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol (2014) 0.93
Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virchows Arch (2003) 0.93
Leptin administration exacerbates thioacetamide-induced liver fibrosis in mice. World J Gastroenterol (2005) 0.90
The β-catenin pathway contributes to the effects of leptin on SREBP-1c expression in rat hepatic stellate cells and liver fibrosis. Br J Pharmacol (2013) 0.88
Leptin, liver, and obese mice--fibrosis in the fat lane. Hepatology (2002) 0.87
Serum levels of apoptosis inhibitor of macrophage are associated with hepatic fibrosis in patients with chronic hepatitis C. BMC Gastroenterol (2014) 0.87
p38 mitogen-activated protein kinase and liver X receptor-α mediate the leptin effect on sterol regulatory element binding protein-1c expression in hepatic stellate cells. Mol Med (2012) 0.85
Association between leptin, metabolic factors and liver histology in patients with chronic hepatitis C. Can J Gastroenterol (2007) 0.84
Expression of leptin receptors in hepatic sinusoidal cells. Comp Hepatol (2004) 0.84
Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis. World J Gastroenterol (2015) 0.83
Risk factors and mechanisms of non-alcoholic steatohepatitis. Pathophysiology (2008) 0.83
Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis. World J Gastroenterol (2009) 0.83
Serum leptin levels, hepatic leptin receptor transcription, and clinical predictors of non-alcoholic steatohepatitis in obese bariatric surgery patients. Surg Endosc (2007) 0.82
A peroxisome-proliferator activated receptor-gamma ligand could regulate the expression of leptin receptor on human hepatic stellate cells. Histochem Cell Biol (2007) 0.82
Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis. Biochim Biophys Acta (2015) 0.82
Leptin in the field of hepatic fibrosis: a pivotal or an incidental player? Dig Dis Sci (2006) 0.80
The effects of diet composition on body fat and hepatic steatosis in an animal (Peromyscus californicus) model of the metabolic syndrome. Comp Med (2011) 0.80
Leptin induces an inflammatory phenotype in lean Wistar rats. Mediators Inflamm (2010) 0.77
Adiponectin-derived active peptide ADP355 exerts anti-inflammatory and anti-fibrotic activities in thioacetamide-induced liver injury. Sci Rep (2016) 0.77
Purinergic receptor X7 mediates leptin induced GLUT4 function in stellate cells in nonalcoholic steatohepatitis. Biochim Biophys Acta (2015) 0.75
GATA binding protein 3 is correlated with leptin regulation of PPARγ1 in hepatic stellate cells. J Cell Mol Med (2016) 0.75
Adipokines in Liver Cirrhosis. Int J Mol Sci (2017) 0.75
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology (2005) 9.39
α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology (2013) 3.27
Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology (2002) 2.97
Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Liver Transpl (2014) 2.77
A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis (2013) 2.30
Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep (2003) 2.16
EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer (2006) 1.97
Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun (2004) 1.93
H. pylori and gastric cancer: the Asian enigma. Am J Gastroenterol (2002) 1.88
Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology (2005) 1.85
Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J Hepatol (2008) 1.85
Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol (2010) 1.80
Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol (2005) 1.74
Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice. Hepatology (2009) 1.71
Targeting lipid metabolism in the treatment of hepatitis C virus infection. J Infect Dis (2008) 1.62
Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol (2010) 1.61
Loss of autophagy promotes murine acetaminophen hepatotoxicity. J Gastroenterol (2011) 1.61
Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother (2005) 1.59
A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res (2010) 1.58
Phytobezoars. Intern Med (2008) 1.57
Occult regurgitation of pancreatic juice into the biliary tract: diagnosis with secretin injection magnetic resonance cholangiopancreatography. Gastrointest Endosc (2002) 1.55
Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha. J Infect Dis (2004) 1.55
Community-acquired pneumonia and nursing home-acquired pneumonia in the very elderly patients. Respir Med (2010) 1.54
Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol (2002) 1.53
Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab (2012) 1.50
Improvement of gastric atrophy after Helicobacter pylori eradication therapy. J Clin Gastroenterol (2003) 1.50
Liver stiffness measured by magnetic resonance elastography as a risk factor for hepatocellular carcinoma: a preliminary case-control study. Eur Radiol (2012) 1.45
Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology (2010) 1.44
Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology (2011) 1.43
Anemia caused by a gastric inflammatory fibroid polyp. Gastrointest Endosc (2007) 1.42
Negative regulation of intracellular hepatitis C virus replication by interferon regulatory factor 3. J Gastroenterol (2006) 1.41
SMAD and p38 MAPK signaling pathways independently regulate alpha1(I) collagen gene expression in unstimulated and transforming growth factor-beta-stimulated hepatic stellate cells. J Biol Chem (2005) 1.36
Liver diseases and metabolic syndrome. J Gastroenterol (2008) 1.33
Translocation of iron from lysosomes into mitochondria is a key event during oxidative stress-induced hepatocellular injury. Hepatology (2008) 1.31
Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum Mol Genet (2011) 1.31
Senescence marker protein-30 knockout mouse liver is highly susceptible to tumor necrosis factor-alpha- and Fas-mediated apoptosis. Am J Pathol (2002) 1.30
Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter (2009) 1.29
Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci U S A (2008) 1.24
Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol (2005) 1.24
Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone. J Pharmacol Exp Ther (2003) 1.24
The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol Res (2005) 1.23
Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun (2002) 1.21
Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production. Gastroenterology (2002) 1.20
Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology (2011) 1.19
CD1d-restricted natural killer T cells contribute to hepatic inflammation and fibrogenesis in mice. J Hepatol (2010) 1.19
Dietary glycine prevents chemical-induced experimental colitis in the rat. Gastroenterology (2003) 1.18
Regulation of hepatitis C virus replication by interferon regulatory factor 1. J Virol (2004) 1.16
Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion: a possible pathogenic mechanism of ulcerative colitis. J Med Microbiol (2009) 1.11
Ease of early gastric cancer demarcation recognition: a comparison of four magnifying endoscopy methods. J Gastroenterol Hepatol (2009) 1.11
ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol Res (2010) 1.09
Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun (2007) 1.08
Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy. J Gastroenterol (2009) 1.08
Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. J Magn Reson Imaging (2011) 1.08
Magnetic resonance elastography for staging liver fibrosis in chronic hepatitis C. Magn Reson Med Sci (2012) 1.08
Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers. Oncogene (2004) 1.04
Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res (2014) 1.04
Autoimmune hepatitis in primary Sjogren's syndrome: pathological study of the livers and labial salivary glands in 17 patients with primary Sjogren's syndrome. Pathol Int (2005) 1.02
Development of plaque assays for hepatitis C virus-JFH1 strain and isolation of mutants with enhanced cytopathogenicity and replication capacity. Virology (2007) 1.02
Coexistence of esophageal superficial carcinoma and multiple leiomyomas: A case report. World J Gastroenterol (2006) 1.01
Role of adipocytokines in hepatic fibrogenesis. J Gastroenterol Hepatol (2007) 1.01
Chronic pancreatitis: Asia-Pacific consensus report. J Gastroenterol Hepatol (2002) 1.01
Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. Cancer (2013) 1.00
Chronic hepatitis delta virus infection with genotype IIb variant is correlated with progressive liver disease. J Gen Virol (2003) 1.00
Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol (2006) 1.00